Fuyuan Pharmaceutical: Bemeprost Topical Gel Receives Approval for Clinical Trial Notification

MetaMuskRat · 2026-04-02T04:07:05+00:00

People's Financial News, March 31 — Fuyuan Pharmaceutical(601089) announced on March 31 that its wholly-owned subsidiary Anhui Fuyuan has received the "Drug Clinical Trial Approval Notice" for Bemeprostil Topical Solution issued by the National Medical Products Administration. This product promotes eyelash growth, making eyelashes longer, thicker, and darker, and is used to treat eyelash hypotrichosis.

MetaMuskRat

2026-04-02 04:07:05

People’s Finance News on March 31: Fuyuan Pharmaceutical (601089) announced on March 31 that its wholly owned subsidiary, Anhui Fuyuan, received the “Drug Clinical Trial Approval Notice” issued and approved by the National Medical Products Administration (NMPA) for bimatoprost eyelash solution. By promoting eyelash growth, this product makes eyelashes longer, denser, and darker, and is used to treat hypotrichosis of the eyelashes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.